Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$55.5M
2 rounds on record
Latest round
$30M
Venture round · Jun 2025 · 15 mo ago
Team
20
US Form 5500 (plan participants) · Dec 2025 · +100% in a year
Backers
2
Atlas Venture, OrbiMed
The money's age
Due for its next round
15 months since the last round · not hiring
Momentum
0/100
no fresh signals
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jun 2025 $30M — SEC Form D
Venture round Jul 2024 $25.5M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Renasant Bio, Inc. sec
Founders and leadersfrom filings, registers and the company's site
Thomas GustafsonExecutive OfficerSEC Form D
Emily ConleyExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
A new path forpatients with Chronic Kidney Disease. At Pathalys Pharma, Inc. we are committed to improving the lives of patients through…
SomatusVenture round $60.1M · 5 yr ago • Founded 2017 • 201-500 employees
Somatus is a leader in value-based kidney care working alongside health plans and providers to help prevent the progression of kidney…
Evlabio11-50 employees
Creating innovative therapies for chronic kidney disease patients. Addressing left ventricular hypertrophy with monoclonal antibody…
Strive HealthVenture round $550M · 12 mo ago • Founded 2018 • 501-1000 employees • 51 roles
Strive Health is a value-based kidney care company based in Denver, Colorado, that works with health plans, health systems and…
CalyxoVenture round $40.1M · 5 mo ago • Founded 2016 • 51-200 employees • 10 roles
Calyxo, Inc. is focused on improving care for patients with kidney stones. CVAC System is the world's first all-in-one kidney stone…
HotSpot Therapeutics201-500 employees
Pioneering a new class of allosteric medicines for the treatment of autoimmune disease. At HotSpot Therapeutics, we are pioneering a new…

Overview

Correctors and Potentiators for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Transforming the Treatment of ADPKD.

People

Thomas Gustafson
Executive Officer
Emily Conley
Executive Officer, Director
Evan Caplan
Director
Natalie Holles
Director
Charlotte McKee
Director
Deborah Palestrant
Director
Anna French
Director
Kevin Bitterman
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Berkeley United States
HQ
50-200 est. staff

Financials

Total raised
$55.5M
Latest round
Venture - Series Unknown
Funding rounds
2
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $30M Details
Venture - Series Unknown 2024 $25.5M Details